Nanox Release Technology
Buenos Aires, Argentina· Est.
Nanox creates nanocarrier formulations to enhance delivery of oncology and infectious disease drugs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Nanox creates nanocarrier formulations to enhance delivery of oncology and infectious disease drugs.
OncologyInfectious DiseasesHematologyEndocrinology
Technology Platform
Nanox employs liposomes, PEG‑ylated liposomes, biodegradable microspheres, microfluidic particle production, and proprietary GM1 ganglioside nanomicelles to improve drug solubility, stability, biodistribution, and controlled release.
Opportunities
Nanox can leverage its nanocarrier expertise to secure licensing deals for complex generics and to attract partnership funding for its oncology depot programs, tapping the growing demand for targeted, long‑acting formulations.
Risk Factors
Regulatory approval pathways for novel nanocarriers are uncertain, and scaling manufacturing while maintaining product consistency may pose significant technical and financial challenges.
Competitive Landscape
Key competitors include Lipocine, NanoCarrier, and major pharma R&D units developing liposomal and polymer‑based delivery; Nanox differentiates through its GM1 nanomicelle platform and flexible contract manufacturing services.